153. Molnupiravir Exhibits a High Barrier to the Development of SARS-CoV-2 Resistance in vitro
Julie Strizki(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jay A. Grobler(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nicholas Murgolo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Beth Hutchins(Merck & Co., Inc., Rahway, NJ, USA (United States)), David D. Ho(Columbia University), John Gaspar(Beth Israel Deaconess Medical Center), John A. Howe(Merck & Co., Inc., Rahway, NJ, USA (United States)), Daria Hazuda(United States Military Academy), Hiroshi Mohri(Aaron Diamond AIDS Research Center)
Cited by 3
Related Papers
Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy
|Science|1997|3.1k
Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques
|The Journal of Experimental Medicine|1999|1.4k